Pharma-Bio Serv FY26 Q2 net income more than doubled to $233,000; revenue rises 11.83% to $2.7 million

PHARMA-BIO SERVICES INC

PHARMA-BIO SERVICES INC

PBSV

0.00
  • Pharma-Bio Serv posted fiscal Q2 net income of USD 233,000, up 145.26% from a year earlier; EPS rose to USD 0.01.
  • Revenue climbed 11.83% to USD 2.7 million, led by Puerto Rico at USD 1.45 million; U.S. revenue fell to USD 620,000.
  • Gross profit increased 10.13% to USD 902,000, while the gross margin narrowed 0.5 percentage points to 33.4%.
  • Selling, general and administrative expenses dropped 17.45% to USD 757,000, mainly on about USD 100,000 lower occupancy costs.
  • Working capital totaled about USD 10.2 million as of April 30, 2026; the company repurchased 4,300 shares during the six months ended April 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma-Bio Serv Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-005986), on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.